BACKGROUND: To determine the effectiveness of pharmacologic prophylaxis in preventing clinically relevant venous thromboembolic (VTE) events and deaths after surgery. The Surgical Care Improvement Project recommends that VTE pharmacologic prophylaxis be given within 24 hours of the operation. The bulk of evidence supporting this recommendation uses radiographic end points. STUDY DESIGN: The Surgical Care and Outcomes Assessment Program is a Washington State quality improvement initiative with data linked to hospital admission/discharge and vital status records. We compared the rates of death, clinically relevant VTE, and a composite adverse event (CAE) in the 90 days after elective, colon/rectal resections, based on receipt of pharmacologic prophylaxis (within 24 hours of surgery) at 36 Surgical Care and Outcomes Assessment Program hospitals (2005-2009). RESULTS: Of 4,195 (mean age 61.1 ± 15.6 years; 54.1% women) patients, 56.5% received pharmacologic prophylaxis. Ninety-day death (2.5% vs 1.6%; p = 0.03), VTE (1.8% vs 1.1%; p = 0.04), and CAE (4.2% vs 2.5%; p = .002) were lower in those who received pharmacologic prophylaxis. After adjustment for patient and procedure characteristics, the odds were 36% lower for CAE (odds ratio = 0.64; 95% CI, 0.44-0.93) with pharmacologic prophylaxis. In any given quarter, hospitals where patients more often received pharmacologic prophylaxis (highest tertile of use) had the lowest rates of CAE (2.3% vs 3.6%; p = 0.05) compared with hospitals in the lowest tertile. CONCLUSIONS: Using clinical end points, this study demonstrates the effectiveness of VTE pharmacologic prophylaxis in patients having elective colorectal surgery. Hospitals that used pharmacologic prophylaxis more often had the lowest rates of adverse events.
BACKGROUND: To determine the effectiveness of pharmacologic prophylaxis in preventing clinically relevant venous thromboembolic (VTE) events and deaths after surgery. The Surgical Care Improvement Project recommends that VTE pharmacologic prophylaxis be given within 24 hours of the operation. The bulk of evidence supporting this recommendation uses radiographic end points. STUDY DESIGN: The Surgical Care and Outcomes Assessment Program is a Washington State quality improvement initiative with data linked to hospital admission/discharge and vital status records. We compared the rates of death, clinically relevant VTE, and a composite adverse event (CAE) in the 90 days after elective, colon/rectal resections, based on receipt of pharmacologic prophylaxis (within 24 hours of surgery) at 36 Surgical Care and Outcomes Assessment Program hospitals (2005-2009). RESULTS: Of 4,195 (mean age 61.1 ± 15.6 years; 54.1% women) patients, 56.5% received pharmacologic prophylaxis. Ninety-day death (2.5% vs 1.6%; p = 0.03), VTE (1.8% vs 1.1%; p = 0.04), and CAE (4.2% vs 2.5%; p = .002) were lower in those who received pharmacologic prophylaxis. After adjustment for patient and procedure characteristics, the odds were 36% lower for CAE (odds ratio = 0.64; 95% CI, 0.44-0.93) with pharmacologic prophylaxis. In any given quarter, hospitals where patients more often received pharmacologic prophylaxis (highest tertile of use) had the lowest rates of CAE (2.3% vs 3.6%; p = 0.05) compared with hospitals in the lowest tertile. CONCLUSIONS: Using clinical end points, this study demonstrates the effectiveness of VTE pharmacologic prophylaxis in patients having elective colorectal surgery. Hospitals that used pharmacologic prophylaxis more often had the lowest rates of adverse events.
Authors: David Bergqvist; Giancarlo Agnelli; Alexander T Cohen; Amiram Eldor; Paul E Nilsson; Anne Le Moigne-Amrani; Flavia Dietrich-Neto Journal: N Engl J Med Date: 2002-03-28 Impact factor: 91.245
Authors: Drahomir Aujesky; Pierre-Marie Roy; Franck Verschuren; Marc Righini; Joseph Osterwalder; Michael Egloff; Bertrand Renaud; Peter Verhamme; Roslyn A Stone; Catherine Legall; Olivier Sanchez; Nathan A Pugh; Alfred N'gako; Jacques Cornuz; Olivier Hugli; Hans-Jürg Beer; Arnaud Perrier; Michael J Fine; Donald M Yealy Journal: Lancet Date: 2011-06-22 Impact factor: 79.321
Authors: William H Geerts; Graham F Pineo; John A Heit; David Bergqvist; Michael R Lassen; Clifford W Colwell; Joel G Ray Journal: Chest Date: 2004-09 Impact factor: 9.410
Authors: N Alhassan; M Trepanier; C Sabapathy; P Chaudhury; A S Liberman; P Charlebois; B L Stein; L Lee Journal: Tech Coloproctol Date: 2018-12-19 Impact factor: 3.781
Authors: Daniel W Nelson; Vlad V Simianu; Amir L Bastawrous; Richard P Billingham; Alessandro Fichera; Michael G Florence; Eric K Johnson; Morris G Johnson; Richard C Thirlby; David R Flum; Scott R Steele Journal: JAMA Surg Date: 2015-08 Impact factor: 14.766
Authors: U O Gustafsson; M J Scott; W Schwenk; N Demartines; D Roulin; N Francis; C E McNaught; J Macfie; A S Liberman; M Soop; A Hill; R H Kennedy; D N Lobo; K Fearon; O Ljungqvist Journal: World J Surg Date: 2013-02 Impact factor: 3.352
Authors: M Francesca Monn; Xuan Hui; Brandyn D Lau; Michael Streiff; Elliott R Haut; Elizabeth C Wick; Jonathan E Efron; Susan L Gearhart Journal: Dis Colon Rectum Date: 2014-04 Impact factor: 4.585
Authors: Peter K Henke; Shipra Arya; Chris Pannucci; Jim Kubus; Samantha Hendren; Michael Engelsbe; Darrell Campbell Journal: Surgery Date: 2012-10 Impact factor: 3.982
Authors: Sha'Shonda L Revels; Sandra L Wong; Mousumi Banerjee; Huiying Yin; John D Birkmeyer Journal: Ann Surg Oncol Date: 2014-04-08 Impact factor: 5.344